136 related articles for article (PubMed ID: 26083291)
1. New drugs 2015, part 2.
Hussar DA
Nursing; 2015 Jul; 45(7):34-41; quiz 41-2. PubMed ID: 26083291
[No Abstract] [Full Text] [Related]
2. Three new agents added to the arsenal to fight MRSA.
Strain J
S D Med; 2014 Dec; 67(12):513-4. PubMed ID: 25571620
[No Abstract] [Full Text] [Related]
3. Dalbavancin, tedizolid phosphate, oritavancin diphosphate, and vedolizumab.
Hussar DA; Nguyen A
J Am Pharm Assoc (2003); 2014; 54(6):658-62. PubMed ID: 25379985
[No Abstract] [Full Text] [Related]
4. Drug updates and approvals: 2014 in review.
Sigler J
Nurse Pract; 2014 Dec; 39(12):14-23; quiz 23-4. PubMed ID: 25350291
[TBL] [Abstract][Full Text] [Related]
5. Antibiotics.
Dalal KS; Bridgeman MB
Nursing; 2017 Mar; 47(3):70. PubMed ID: 28225406
[No Abstract] [Full Text] [Related]
6. The top 10 drug trends right now.
Johnson MS
Nurs Manage; 2013 Jul; 44(7):34-40; quiz 40-1. PubMed ID: 23764906
[No Abstract] [Full Text] [Related]
7. NewDrugs 2017, part 2.
Hussar DA
Nursing; 2017 Jul; 47(7):28-36. PubMed ID: 28590960
[No Abstract] [Full Text] [Related]
8. New drugs 2016, part 2.
Hussar DA
Nursing; 2016 Jul; 46(7):26-33. PubMed ID: 27273173
[No Abstract] [Full Text] [Related]
9. New Gram-Positive Agents: the Next Generation of Oxazolidinones and Lipoglycopeptides.
Crotty MP; Krekel T; Burnham CA; Ritchie DJ
J Clin Microbiol; 2016 Sep; 54(9):2225-32. PubMed ID: 26962092
[TBL] [Abstract][Full Text] [Related]
10. Current and future trends in antibiotic therapy of acute bacterial skin and skin-structure infections.
Russo A; Concia E; Cristini F; De Rosa FG; Esposito S; Menichetti F; Petrosillo N; Tumbarello M; Venditti M; Viale P; Viscoli C; Bassetti M
Clin Microbiol Infect; 2016 Apr; 22 Suppl 2():S27-36. PubMed ID: 27125562
[TBL] [Abstract][Full Text] [Related]
11. Drug updates and approvals: 2017 in review.
Mospan G; Mospan C; Vance S; Bradshaw A; Meosky K; Bowles K
Nurse Pract; 2017 Dec; 42(12):8-16. PubMed ID: 29176433
[TBL] [Abstract][Full Text] [Related]
12. Antimicrobial development in the era of emerging resistance.
Sorlozano A; Carrasco C; Cabeza J; Villegas E; Gutierrez J
Mini Rev Med Chem; 2009 Jul; 9(8):938-55. PubMed ID: 19601889
[TBL] [Abstract][Full Text] [Related]
13. 2015 new drug update.
Hussar DA
Consult Pharm; 2015 Apr; 30(4):192-208. PubMed ID: 25893698
[TBL] [Abstract][Full Text] [Related]
14. New Drugs 2017, part 1.
Hussar DA
Nursing; 2017 Feb; 47(2):32-39. PubMed ID: 28060244
[No Abstract] [Full Text] [Related]
15. Apremilast, albiglutide, and empagliflozin.
Hussar DA; Yenner S
J Am Pharm Assoc (2003); 2014; 54(5):562-6. PubMed ID: 25216888
[No Abstract] [Full Text] [Related]
16. A comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin.
Guskey MT; Tsuji BT
Pharmacotherapy; 2010 Jan; 30(1):80-94. PubMed ID: 20030476
[TBL] [Abstract][Full Text] [Related]
17. New drugs 2015, part 3.
Hussar DA
Nursing; 2015 Oct; 45(10):30-7; quiz 37-8. PubMed ID: 26352370
[No Abstract] [Full Text] [Related]
18. New drugs 2015, part 1.
Hussar DA
Nursing; 2015 Apr; 45(4):40-8; quiz 48-9. PubMed ID: 25719949
[No Abstract] [Full Text] [Related]
19. New Drugs 2019, part 3.
Hussar DA
Nursing; 2019 Aug; 49(8):24-32. PubMed ID: 31268951
[TBL] [Abstract][Full Text] [Related]
20. New Drugs 2021, Part 1.
Hussar DA
Nursing; 2021 Feb; 51(2):36-44. PubMed ID: 33953097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
